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Abstract
Background: Invasive fungal infections such as candidiasis constitute an increasingly important medical problem.
Drugs currently used for the treatment of candidiasis include polyenes (such as Amphotericin B) and azoles.
Amphotericin B (AmpB) presents several limitations such as its nephrotoxicity and limited solubility. We have
developed two novel lipid-based AmpB formulations which in vivo show less nephrotoxicity and enhanced
solubility compared to Fungizone™ a commercial AmpB formulation.
The purpose of this study was to determine the cytotoxicity of Fungizone™, Ambisome™ and two novel AmpB
formulations (iCo-009 and iCo-010) against Candida albicans, human kidney (293T) cells and monocytic (THP1) cells.
Methods: Cell cytotoxicity to the AmpB formulations was evaluated by MTS and LDH assays. In vitro anti-Candida
albicans activity was assessed after a 48 h drug incubation.
Results: None of the AmpB formulations tested showed cytotoxicity against 293T cells. In the case of THP1 cells
only Fungizone™ and Ambisome™ showed cytotoxicity at 500 μg/L (n = 4-10, p < 0.05).
The calculated EC50 to Candida albicans for the different formulations was as follows: 26.8 ± 2.9 for iCo-010, 74.6 ±
8.9 for iCo-009, 109 ± 31 for Ambisome™ and 87.1 ± 22 for Fungizone™ (μg of AmpB/L, n = 6-12, p < 0.05).
Conclusions: The AmpB formulations analyzed were not cytotoxic to 293T cells. Cytotoxicity in THP1 cells was
observed for Fungizone™ and Ambisome™, but not with the novel AmpB formulations. iCo-010 had higher
efficacy compared to other three AmpB formulations in the Candida albicans model.
The absence of cytotoxicity as well as its higher efficacy for the Candida model compared to Fungizone™ and
Ambisome™ suggest that iCo-010 has potential in treating candidiasis.
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1. Background
Invasive fungal infections constitute an increasingly
important medical problem due to the growth of immu-
nodeficient populations, the development of antifungal
resistance and limitations in the efficacy and toxicity of
current antifungals [1]. Candida species are the most
common cause of nosocomial invasive mycosis and are
the leading cause of related mortality [2]. An increasing
rate of candidaemia [3] as well as the emergence of
drug resistant strains [4] support the efforts in discover-
ing novel therapeutic approaches [1].
Drugs currently used for the treatment of candidiasis
include polyenes (such as Amphotericin B AmpB),
azoles (fluconazole), echinocandins and flucytosine. Lim-
ited therapeutic efficiency and drug resistance have led
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the use of new analogs of existing drugs [1].
Amphotericin B (AmpB) is a treatment of choice for
systemic fungal infections [5]. The mechanism of action
of AmpB involves its binding to ergosterol in the fungal
cell membrane, producing pores in the membrane
which leads to ion loss and cell death [6]. Recently it
has been described that AmpB can also elicit cell death
through the induction of a strong oxidative burst [7].
Acquired resistance to Amphotericin B in Candida spe-
cies, though rare, has been reported previously [8,9].
This AmpB resistance has been correlated with
decreased levels of ergosterol in the plasma membrane
and has been accompanied with azole resistance [10,11].
One of the major limitations associated with AmpB is
its nephrotoxicity [12]. Another issue related to AmpB
is its poor solubility that limits its route of administra-
tion [13]. The development of an effective, safe, and
inexpensive oral formulation of amphotericin B would
have many applications for the treatment of fungal dis-
eases. The new oral amphotericin B formulations devel-
oped by our group, iCo-009 and iCo-010, show efficacy
in vivo against leishmaniasis [14,15], aspergillosis and
candidiasis [16].
T h ep u r p o s eo ft h ep r e s e n ts t u d yw a st od e t e r m i n ei f
four different formulations of AmpB (iCo-009, iCo-010,
Fungizone™ and Ambisome™) were cytotoxic in
human monocytic, human kidney cells and Candida
albicans.
2. Results and Discussion
The first objective of our study was to determine the
AmpB-induced cytotoxicity in two human cell lines,
293T kidney and THP1 monocytic cells. No evidence of
cytotoxicity was found in any of the three AmpB formu-
lations used (Fungizone™, iCo-009 and iCo-010) at the
doses tested (Figure 1, n = 4) using a respiration assay
(MTS) in the kidney 293T cells. The vehicle controls for
both iCo-009 and iCo-010 did not show a toxic effect
(data not shown). At the highest AmpB dose analyzed
(10,000 μg/L), there was a reduction of 20% in the
respiration rate of the cells treated with Fungizone™,
however, it didn’t reach statistical significance. In terms
of cytotoxicity in THP1 monocytic cells of the four
AmpB formulations at the doses analyzed (0 to 500 μg/
L), differences were shown between the MTS (Figure 2a,
n = 4-10) and LDH (Figure 2b, n = 6) results. No
changes in viability were found with the LDH assay at
any of the AmpB concentrations analyzed. The LDH
results were corrected by the amount of protein in each
treatment group. There was also no difference in protein
content in the different treatment groups. However, the
Normalized MTS results exhibited a reduced respiration
rate at 500 μg/L for both Fungizone™ (0.71 ± 0.04) and
Ambisome™ (0.72 ± 0.17) compared to controls (1.00).
Previously, others [17] have described a difference in
the degree of cellular activation by AmpB in the 293
and THP1 cell lines. This disparity was accounted by
the differential expression of the TLR2, highly expressed
in THP1 cells and expressed at very low levels in 293
cells. The new oral formulations, iCo-009 and iCo-010,
d i dn o ts h o wa n ye v i d e n c eo ft o x i c i t ya tt h eh i g h e s t
concentration analyzed in 293T cells (10,000 μg/L, Fig-
ure 1). The limited TLR2 expression in 293T cells may
explain this lack of cytotoxicity that was observed even
at large doses of AmpB compared with a cytotoxic effect
of AmpB in THP1 cells at a lower concentration (500
μg/L).
The difference in cytotoxicity found in THP1 cells
between the LDH and MTS assays could be accounted
by the fact that the MTS assay relies on the accessibility
of the substrate to the respiratory machinery of the cell
(i.e. expression and activity of transporters). In the case
of LDH there is no active transport factor(s) as it is an
index of the cell breakdown and the release of LDH
enzyme to the medium. The drug concentration that eli-
cits toxicity in the THP1 monocytes with Fungizone™
and Ambisome™ can be compared with the serum drug
levels obtained in patients. After a standard dose of
AmpB (0.3 mg/kg on days 1 and 2 followed by increas-
ing doses to 0.5 mg/kg) for patient therapy, the expected
serum AmpB levels can reach 200 μg/L [18]. Few stu-
dies have assessed the AmpB-induced cytotoxicity in
monocytes and macrophages. Sesana et al., [19] exam-
ined the in vitro activity of AmpB cochleates against
Leishmania chagasi and the cytotoxic effect on mouse
peritoneal macrophages using AmpB deoxycholate (Fun-
gizone™) as a control. They found that the AmpB deox-
ycholate (Fungizone™)w a sc y t o t o x i ct om o u s e
peritoneal macrophages at a concentration of 1250 μg/L,
while the AmpB cochleates were not toxic at that AmpB
concentration.
T h es e c o n do b j e c t i v eo fo u rs t u d yw a st od e t e r m i n e
the efficacy of the novel AmpB formulations in an in
vitro Candida albicans model. Unfortunately, frequently
there is limited correlation between in vitro susceptibil-
ity determination and patient response [20]. However,
use of RPMI medium supplemented with dextrose
showed improvement in assessing Candida albicans
antibiotic susceptibility [21]. Thus this methodology was
used in the present study. The results (Figure 3 and
Table 1) showed that iCo-010 had a lower EC50 than
Fungizone™,A m b i s o m e ™ and iCo-009 for this ATCC
Candida albicans reference strain (n = 6-12 experi-
ments). The EC50 calculated for AmpB (as Fungi-
zone™) for the Candida albicans reference strain 18804
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previously obtained for this strain in an Etest [22].
iCo-009 was previously compared to Abelcet
® in an in
vivo study in Candida albicans-infected male rats [16].
In that report, iCo-009 exhibited significant reduction in
viable colony forming units of Candida from kidney
homogenates compared to Abelcet
®.
3. Conclusions
We have tested the cytotoxicity and efficacy of four
AmpB formulations in two human cell lines and a Can-
dida albicans model, respectively. Fungizone™ and
Ambisome™, but not iCo-009 and iCo-010, show cyto-
toxicity in human monocytes at a concentration of 500
μg/L. iCo-010 shows a higher efficacy compared to iCo-
009, Ambisome™ and Fungizone™ in the Candida
albicans model. The lack of toxicity and efficacy of iCo-
010, a novel oral AmpB formulation, warrant future in
vivo Candida albicans studies to determine its therapeu-
tic index.
4. Materials and methods
4.1. Novel lipid oral Amphotericin B formulations
The description of the composition and development of
the two novel lipid oral Amphotericin B formulations
can be found elsewhere iCo-009 [16] and iCo-010 [15].
AmpB concentration was analyzed by HPLC as pre-
viously described [16]. For the cytotoxicity and efficacy
studies we used as negative controls medium alone and
medium containg the vehicle controls for both iCo-009
and iCo-010. No cytotoxicity was found when any of
these controls were used (data not shown).
4.2. Cytotoxicity assay on 293T cells
Human embryonic kidney cells (293T ATCC CRL
11268) were kindly provided by Dr JS Hill (St Paul’s
Figure 1 Cytotoxicity in 293T cells: Dose-response effects of Fungizone™, iCo-009 and iCo-010 on cytotoxicity on human embryonic (293T)
kidney cells. The cells were exposed for 48 h with different drug concentrations (0, 250, 500, 1000, 5000 and 10,000 μg AmpB/L). MTS values
were corrected for protein determination and normalized to the control cells. Data are reported as means ± standard deviation of four
experiments (eight replicates per experiment).
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as assessed using an MTS assay (Figure 2a). The cells were exposed for 48 h with different drug concentrations (31.25, 62.5, 125, 250 and
500 μg AmpB/L). The cells were washed and incubated with the MTS reagent for 90 min. Data are reported as means ± standard deviation of
four to ten experiments, * p < 0.05, eight replicates per experiment). Dose-response effects of Fungizone™, Ambisome™, iCo-009 and iCo-010
on cytotoxicity in human monocytic (THP1) cells as assessed using an LDH assay (Figure 2b). The cells were exposed for 48 h with different
drug concentrations (31.25, 62.5, 125, 250 and 500 μg AmpB/L). An aliquot of the medium was incubated with the LDH reagent. Data are
reported as means ± standard deviation of six experiments (four replicates per experiment).
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complete DMEM without phenol red at 37°C (5% CO2)
in T75 flasks. At near confluency, the cells were trypsi-
nized and transferred to either additional flasks or to
96-well plates (previously coated with Poly L-lysine and
seeded at a density of 10,000 cells/well). Twenty four
hours post seeding, the adherent cells were washed and
incubated with different concentrations of AmpB formu-
lations (250 to 10,000 μg/L of AmpB) for 48 h. Percent
AmpB-mediated cytotoxicity was determined using the
MTS conversion assay (Promega Corp, Madison, WI), as
previously described [23].
4.3. Cytotoxicity assay on THP1 cells
Human monocytic THP1 cells (ATCC TIB-202) were
kindly provided by Dr JS Hill (St Paul’s Hospital, UBC,
Vancouver, BC). Cells were grown in complete RPMI
without phenol red at 37°C (5% CO2) in T75 flasks.
Before the cells reached a concentration of one million
per mL, the cells were transferred to either additional
flasks or to 96-well plates and seeded at a density of
20,000 cells/well with the addition of PMA (10 ng/mL
final) to allow the cells to differentiate overnight.
Twenty four hours post seeding, the differentiated cells
were washed and the different concentrations of AmpB
formulations were added (31 to 500 μg/L of AmpB) for
48 h. After a 90 min incubation with the MTS reagent,
percent AmpB-mediated cytotoxicity was determined
Figure 3 In vitro Candida efficacy studies. Candida was exposed for 48 h to different doses of Fungizone™, iCo-009 and iCo-010 (0, 15.6,
31.25, 62.5, 125 and 250 μg AmpB/L). A vehicle control with the same lipid composition as iCo-010 was also used at comparable volumes.
Growth was normalized by the corresponding absorbance of the untreated Candida. The vehicle control showed no effect on Candida growth.
(* p < 0.05 n = 6-12 independent experiments, each experiment includes eight replicates).
Table 1 EC50 for AmpB formulations (mean ± SD,
expressed in μg/L of AmpB, n = 6-12, * p < 0.05) tested
in the Candida model
Mean ± SD
Fungizone ™ 87.1 ± 22
Ambisome™ 109 ± 31
iCo-009 74.6 ± 8.9
iCo-010 26.8 ± 2.9 *
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son, WI), as previously described [23] or the LDH assay
(Promega Corp, Madison, WI) as outlined by the manu-
facturer specifications. The MTS and LDH results were
corrected by the amount of protein present in the
respective wells. Purified LDH from the manufacturer
kit was used as a positive control (data not shown).
4.4. Minimum inhibitory concentration determination of
the AmpB formulations on Candida growth in liquid
medium
RPMI without phenol red and supplemented with 10%
Fetal bovine serum, 2% dextrose plus penicillin and
streptomycin was used to prepare dilutions of AmpB
(31.25, 62.5, 125, 250 and 500 μg/L- final drug concen-
tration) from Fungizone™,A m b i s o m e ™, iCo-009 and
iCo-010 (AmpB concentration in the formulations was
determined by HPLC). A vehicle control of iCo-009 and
iCo-010 was used as a negative control. RPMI is the
standard medium used in microplate drug susceptibility
assays and is commonly used for testing of drug sensi-
tivity for both Candida albicans and Cryptococcus neo-
formans [24]. A limitation of the RPMI medium is that
there are frequent overlaps between the EC50 ranges for
isolates that are putatively resistant or susceptible to
Amphotericin B. The supplementation of RPMI medium
with 2% glucose has lead to higher fungal growth rates
and better separation of EC50s for isolates that are puta-
tively resistant to fluconazole [21]. This is the methodol-
ogy that we have used for our experiments.
The Candida albicans (ATCC reference strain 18804)
inoculum was prepared as follows. The fungal cell con-
centration was determined using a hematocytometer.
One hundred microlitres of a 5 × 10
5/mL preparation of
Candida in RPMI was placed in the 96 well plates for a
final concentration of 2.5 × 10
5 cells/mL. Each concen-
tration was analyzed in eight replicates per experiment
(n = 6-12 independent experiments).
The plates were incubated for 48 h at 37°C protected
from the light before analyzing the growth pattern using
a spectrophotometer at 650 nm. A new Candida agar
plate was streaked each week to ensure the viability of
the culture.
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